Endoscopic subureteral injection for treatment of vesicoureteral reflux (VUR) is known to be safe and efficient due to its minimal invasive nature. Being non-migratory, non-antigenic, and biocompatible, Macroplastique (Polydimethylsiloxane) is likely to be stable over time. A 5-year-old boy with a past history of subureteral administration of Macroplastique for unilateral Grade V VUR 4 years ago presented with recurrent gross and microscopic hematuria, along with suprapubic pain. On computed tomography (CT) abdomen, calcified material, suspected to be a stone, was visualized in the bladder. On diagnostic cystoscopy, calcification was seen around the orifice site where Macroplastique injection had been performed. We removed the calcific material by Holmium laser. Endoscopic subureteric implantation has several advantages, but nevertheless, vigilance is needed to detect longterm complications, especially in patients with gross or microscopic hematuria.
Introduction
Vesicoureteral reflux (VUR) is present in about 1% of normal healthy child ren and in 30-50% of children with symptomatic urinary tract infections (UTIs) 1) . The most common presenting symptom of VUR is pyelonephritis, which can lead to renal injury and subsequent renal impairment or endstage renal disease 2) . Children with VUR may be managed either medically or sur gically. The rationale for medical management is prevention of UTI using daily antibiotic prophylaxis, regular timed voiding and, in some cases, anticholi nergic medication. The surgical management of VUR consists of repair of the ureterovesical junction (UVJ) abnormality 3) . In recent years, endoscopic sub ureteral transurethral injection (STING) has become the firstline therapy for children with VUR owing to its high success rate and minimum complica tions 4) . The substance used for endoscopic injection should be nontoxic, bio compatible, nonmigratory, and nonantigenic, causing minimal local in flammation. Macroplastique is one of the most popular bulking agents and has wide application in the medical field, especially in endoscopic manage ment of VUR 5) . We report a case of gross hematuria caused by calcified Macro plastique substance injected to initially treat unilateral VUR.
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Case report
A 5yearold boy presented to our pediatric emergency department with intermittent gross hematuria and supra pubic pain since several months. He was treated with anti biotics for suspected cystitis, whenever he had such symp toms in the past and symptoms were disappeared in several days. He suffered from recurrent febrile UTIs since 4 months of age, and was diagnosed with unilateral grade V VUR and the febrile UTIs were not responsive to prophylactic anti biotics, hence Macroplastique injection was performed at 9 months of age (Fig. 1) .
Followup VCUG performed 3 months after injection showed a resolution of VUR. After 2 years from Macropla stique injection, gross hematuria appeared first time. Also, two times microscopic hematuria and three times gross hematuria broke out. His mother gave a history of trans parent powdery material in his urine frequently, after Ma croplastique injection. Whenever hematuria presented, we checked urine calcium/creatinine ratio and the results were always within age specific reference ranges. Also his 24 hours urine calcium was 19.76 mg (1.31 mg/kg). On exa mination, he was afebrile with stable vital signs. Initial uri nalysis showed isomorphic hematuria and mild proteinuria. We performed CT abdomen, which demonstrated two 0.7 cm hyperdense lesions in the left posterior aspect of the bladder and suspected stones at the UVJ or in the bladder (Fig. 2) . Ultrasonography (US) showed previous mild pel viectasia of the left kidney (0.3 cm) and two hyperechoic foci with posterior acoustic shadowing, in the left posterior aspect of the bladder. However, the lesion did not move with pos ition changes. Therefore, to find out the exact problem, considering a past medical history of Macroplastique in jection, we decided to perform a diagnostic cystoscopy.
On cystoscopy, calcifications were seen, leading to mu cosal erosions around the orifice where Macroplastique injection had been injected previously. The calcifications on the mucosal area causing mucosal erosion were succes sfully removed with the help of laser (Fig. 3) . Symptoms of gross hematuria, suprapubic pain, and dysuria were gradu ally relieved after treatment. We have checked routine uri n alysis and US after seven months from cystoscopy. There were no identifiable calcifications in bladder mucosa al though we cannot exactly evaluate as follow up CT scan was not done. His symptoms have not recurred till date.
Discussion
Endoscopic subureteral injection has gained popularity and has evolved as the prime therapeutic alternative to antibiotic prophylaxis and ureteroneocystostomy, since its initial description by Matouschek in 1981, and its first clinical use reported by O'Donnell and Puri in 1984 6, 7) . In traoperative complications following injection of bulking agent had a remarkably low incidence, and complications were limited to infection and/or bleeding. Postoperative complications were also extremely rare 8) . Several bulking agents with numerous advantages as well as drawbacks have been used to treat reflux, including polytetrafluoroe thylene, collagen, autologous injectables, Macroplastique (Uroplasty, Minnetonka, USA), and dextranomer/hyalu ronic acid copolymer (Deflux; Oceana Therapeutics, Inc, Edison, USA). Among these agents, Macroplastique is one of the most popular agents and has wide application in the medical field. Macroplastique, made of solid silicone elas tomer, a nonbiodegradable substance, is reabsorbed and exchanged with a reactive transudate containing fibroblasts, which then facilitate its encapsulation 4) . Since the success rate was dependent on the kind of bulking agent injected, many studies have demonstrated the overall success rate of each material, and no significant difference was observed in cure rates 4, 9) . Some previous studies have reported that VUR was better corrected in the Macroplastique group (86.2%) than in Deflux group (71.4%) 5) . Most studies focus on success rates, but postoperative complications after en doscopic therapy of VUR, or procedurerelated complica tions (obstruction, contralateral VUR, voiding anomalies) should be evaluated, to confirm overall safety of the pro cedure or operation 1) . One study demonstrated several shortterm complications after endoscopic injection of Macroplastique. Four patients who had recurrent UTIs and unilateral or bilateral VUR underwent endoscopic injection of Macroplastique. Several months after the pro cedure, they developed flank pain, highgrade fever, and oliguria, and were diagnosed with ureteral obstruction, urosepsis, acute renal failure, or VUR. Intravenous anti biotics were administered and percutaneous nephrostomy was performed. However, unfortunately, all the patients had to ultimately undergo ureteroneocystostomy 1) . Recently in Korea, a small number of case reports similar to ours have been published. In one study, a 10yearold girl, underwent subureteral administration of Macropla stique to treat bilateral VUR, following which she had re current pyelonephritis. US revealed two bladder stones (2.0 cm and 1.3 cm) near the right trigonal area of the bladder, 6 years after the endoscopic injection. Complete stone re moval using cystolitholapaxy was performed 10) . In another study, a 38yearold male patient who had undergone Ma croplastique injection 7 years ago due to VUR, had left sided abdominal pain. CT abdomen showed a stone (0.83 cm) near the left UVJ and it was removed using Holmium laser. As seen in our case report, both patients who were injected with Macroplastique several years ago had stones in the bladder or at the UVJ. After removing the stones with laser treatment, recurrent pyelonephritis and abdominal pain disappeared completely 11) . Calcified Macroplastique substance in the submucosa can lead to mucosal erosions as it is grows. If mucosal ero sions get worse, hematuria and symptoms of cystitis may develop, which if untreated, may lead to UVJ obstruction. Considering the increasing number of patients of VUR re ceiving Macroplastique injection, long term standardized followup is required, and physicians should recognize the late complications after endoscopic bulking agent admini stration. Also, recurrent hematuria after endoscopic injec tion should be thoroughly evaluated.
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